๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Role of combination therapy in chronic hepatitis B

โœ Scribed by John D. Scott; Brian McMahon

Book ID
107538462
Publisher
Springer
Year
2009
Tongue
English
Weight
441 KB
Volume
11
Category
Article
ISSN
1522-8037

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Combination therapy for chronic hepatiti
Combination therapy for chronic hepatitis B
โœ R J Fontana; A S Lok ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 132 KB

ing Phase I and Phase II clinical trials. Other forms of experimental treatment that are being examined in in vitro and Currently, interferon alfa is the only approved treatment animal models include antisense oligonucleotides and supfor chronic hepatitis B virus (HBV) infection. A 3-to 6pressive HB

Endpoints of therapy in chronic hepatiti
Endpoints of therapy in chronic hepatitis B
โœ Jordan J. Feld; David K. H. Wong; E. Jenny Heathcote ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 111 KB

Because clearance of hepatitis B virus (HBV) infection is rarely, if ever, achievable, the goals of therapy necessarily focus on prevention of bad clinical outcomes. Ideally, therapies would be shown to prevent tangible clinical endpoints like development of cirrhosis, end-stage liver disease and he